Visionaire™ Versus Standard Instrumentation Safety and Efficacy in Total Knee Arthroplasty (TKA)



Status:Recruiting
Conditions:Arthritis, Osteoarthritis (OA), Orthopedic
Therapuetic Areas:Rheumatology, Orthopedics / Podiatry
Healthy:No
Age Range:Any
Updated:4/21/2016
Start Date:April 2010
End Date:June 2016
Contact:Laura Yacoubian
Email:laura.yacoubian@smith-nephew.com
Phone:1-901-800-3039

Use our guide to learn which trials are right for you!

A Multicenter, Randomized, Clinical Outcome of VISIONAIRE™ Patient Matched Technology vs. Standard Surgical Instrumentation in Total Knee Arthroplasty

The objective of this study is to assess outcomes following TKA, utilizing two surgical
techniques. Patients will be randomized to one of two arms: TKA with standard
instrumentation and TKA with VISIONAIRE™ patient-matched cutting blocks. Data will be
collected at preoperative, operative/discharge, 3 months, 1 year and 2 years after TKA. The
secondary objective of this study is to compare the safety, quality of life, and economic
outcomes of TKA when these two techniques are utilized. This study does not involve
treatment or investigational products, as all components are FDA cleared and are
commercially available.

This is a prospective study comparing VISIONAIRE™ to standard TKA instrumentation. The
objective of this study is to evaluate the safety and efficacy of TKA using VISIONAIRE™ when
compared with standard instrumentation, including device survival, improvement in function
and implant alignment after TKA. This study will also document any device-related, surgical
complications and/or adverse radiographic observations.

In contrast with the control group clinical outcomes following TKA completed with
VISIONAIRE™ have yet to be assessed. The current investigation will determine if there is
any difference in TKA outcomes when VISIONAIRE™ patient matched technology is utilized
versus standard instrumentation. All patients meeting the inclusion/exclusion criteria
specified in this protocol will be asked to participate in the study. If the patient
consents to participate, they will be enrolled in the study and randomized to one of the two
study arms. Patients requiring TKA will be implanted with Legion, Genesis II or Journey BCS
(Smith & Nephew) total knee implant systems. Standard instrumentation will be used to assist
the surgeon in placing the implant in the control group. In the VISIONAIRE™ group, standard
instrumentation will not be used in the surgery. Patients randomized to the VISIONAIRE™ arm
will have an MRI preoperatively that will be used to create the customized cutting blocks.
All patients will have an x-ray at each postoperative interval.

Inclusion Criteria:

Patients must meet all of the inclusion criteria.

1. Patient diagnosed with degenerative arthritis of the knee requiring a unilateral
primary TKA.

2. Patient is of legal age to consent and is skeletally mature.

3. Patient is willing to sign and date an ethics-approved consent form.

4. Patient is willing to be available for two-year follow-up postoperatively

Exclusion Criteria:

Patients must not meet any of the exclusion criteria.

1. Patient is known to have poor bone stock making a TKA unjustifiable.

2. Patient is immuno-suppressed.

3. Patient has physical, emotional or neurological conditions that would compromise the
patient's compliance with postoperative rehabilitation and follow-up.

4. Patient is pregnant or may become pregnant during the course of the study.

5. Patient has a history of prior ipsilateral major knee surgery (e.g. arthroplasty,
high tibial osteotomy, or tibial plateau fracture). Minor prior procedures such as
ACL repair, meniscectomy, or arthroscopy are not excluded.

6. Patient has active, localized or systemic infection.

7. Patient is severely overweight (BMI >40).

8. Patient is a prisoner.

9. Subject has a significant MRI (magnetic resonance imaging) exclusion or
contraindication.

10. Patient has had a total joint arthroplasty of the contralateral limb in the last 12
months.
We found this trial at
7
sites
801 N Rutledge St
Springfield, Illinois 62702
(217) 545-8000
Principal Investigator: Khaled Saleh, MD
Southern Illinois University School of Medicine At SIU School of Medicine, research includes biologically oriented...
?
mi
from
Springfield, IL
Click here to add this to my saved trials
Eugene, Oregon 97401
Principal Investigator: Brick Lantz, MD
?
mi
from
Eugene, OR
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
(402) 559-4000
Principal Investigator: Curtis Hartman, MD
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Park Ridge, Illinois 60068
?
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Saint Louis, Missouri 63131
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Windsor, Victoria 3181
?
mi
from
Windsor,
Click here to add this to my saved trials
Winston-Salem, North Carolina 26157
Principal Investigator: Jason Lang, MD
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials